New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

April 14, 2025 Author: Simone Ndujiuba, PharmD, BCOP In the United States, pancreatic cancer is the fourth leading cause of cancer related death.¹ In 2023, approximately 64,050 people were...

From cutting-edge system solutions to powerful stakeholder partnerships, the Medicaid Enterprise Systems Conference delivered key insights and connections that will shape health care modernization...

Real-world, integrated data follows-up on previous insights, analytics.

Clinical Solutions Vice President (Remote) Job description: The Medicare Part D pharmacy programs manager manages the coordination of benefits in the pharmacy program with Medicare Part D plans,...

High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...

NCCN Recommendations for use of immunoglobulin² Intervention CAR T BsAbs Other indications Immunoglobulin replacement After CAR T-cell therapy, regular immune globulin infusions based on clinical...

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Edwards joins as president, markets.

Designation demonstrates highest level of commitment to quality health care